Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anis Hamid

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
Prostate Cancer and Prostatic Diseases|February 11, 2022
Outcomes in men with metastatic castration-resistant prostate cancer who received sipuleucel-T and no immediate subsequent therapy: experience at Dana Farber and in the PROCEED RegistryXiao X Wei, Lucia Kwak, Anis Hamid, et al.
The Journal of Endocrinology|January 19, 2017
Regulation of aldosterone secretion by mineralocorticoid receptor-mediated signalingCherish Chong, Anis Hamid, Tham Yao, et al.
Annals of Hematology|February 17, 2016
Hodgkin lymphoma: an Australian experience of ABVD chemotherapy in the modern eraAzim Jalali, Francis J Ha, Geoff Chong, et al.
Cancers|May 13, 2023
A Multicenter, Open-Label, Phase I/II Study of FN-1501 in Patients with Advanced Solid TumorsGary Edward Richardson, Raed Al-Rajabi, Dipesh Uprety, et al.
JCO Oncology Practice|November 3, 2025
Interprovider Variation in Initiation of Bone-Modifying Agents for Patients With Prostate CancerAaron P Mitchell, Andrew Salner, Paul Palyca, et al.
Journal for Immunotherapy of Cancer|March 29, 2020
Safety and efficacy of immune checkpoint inhibitors in advanced urological cancers with pre-existing autoimmune disorders: a retrospective international multicenter studyNieves Martinez Chanza, Wanling Xie, Majd Issa, et al.
Prostate Cancer and Prostatic Diseases|January 11, 2022
Definitions of disease burden across the spectrum of metastatic castration-sensitive prostate cancer: comparison by disease outcomes and genomicsPhilip Sutera, Kim Van Der Eecken, Amar U Kishan, et al.
The Prostate|May 6, 2021
A polymorphism in the promoter of FRAS1 is a candidate SNP associated with metastatic prostate cancerVictoria Wang, Milan S Geybels, Kristina M Jordahl, et al.
Arxiv|April 1, 2025
Causes of evolutionary divergence in prostate cancerEmre Esentürk, Atef Sahli, Valeriia Haberland, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Prostate Cancer and Prostatic Diseases|February 11, 2022
Outcomes in men with metastatic castration-resistant prostate cancer who received sipuleucel-T and no immediate subsequent therapy: experience at Dana Farber and in the PROCEED RegistryXiao X Wei, Lucia Kwak, Anis Hamid, et al.
The Journal of Endocrinology|January 19, 2017
Regulation of aldosterone secretion by mineralocorticoid receptor-mediated signalingCherish Chong, Anis Hamid, Tham Yao, et al.
Annals of Hematology|February 17, 2016
Hodgkin lymphoma: an Australian experience of ABVD chemotherapy in the modern eraAzim Jalali, Francis J Ha, Geoff Chong, et al.
Cancers|May 13, 2023
A Multicenter, Open-Label, Phase I/II Study of FN-1501 in Patients with Advanced Solid TumorsGary Edward Richardson, Raed Al-Rajabi, Dipesh Uprety, et al.
JCO Oncology Practice|November 3, 2025
Interprovider Variation in Initiation of Bone-Modifying Agents for Patients With Prostate CancerAaron P Mitchell, Andrew Salner, Paul Palyca, et al.
Journal for Immunotherapy of Cancer|March 29, 2020
Safety and efficacy of immune checkpoint inhibitors in advanced urological cancers with pre-existing autoimmune disorders: a retrospective international multicenter studyNieves Martinez Chanza, Wanling Xie, Majd Issa, et al.
Prostate Cancer and Prostatic Diseases|January 11, 2022
Definitions of disease burden across the spectrum of metastatic castration-sensitive prostate cancer: comparison by disease outcomes and genomicsPhilip Sutera, Kim Van Der Eecken, Amar U Kishan, et al.
The Prostate|May 6, 2021
A polymorphism in the promoter of FRAS1 is a candidate SNP associated with metastatic prostate cancerVictoria Wang, Milan S Geybels, Kristina M Jordahl, et al.
Arxiv|April 1, 2025
Causes of evolutionary divergence in prostate cancerEmre Esentürk, Atef Sahli, Valeriia Haberland, et al.
Pageof 1